Skip to content

Study · Not a test of the peptide alone · 2021

1 result

Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.

Wu X, Zhou J, Sun Y, Ding H, Chen G, Xie W, Piao H, Xu X, Jiang W, Ma H, Ma A, Chen Y and 11 more

Show all authors

Xu M, Cheng J, Xu Y, Meng T, Wang B, Chen S, Shi Y, Kong Y, Ou X, You H, Jia J

Hepatology international18 Jan 2021Cited by 7 (Europe PMC)

PMID33460002 (opens in a new tab)DOI10.1007/s12072-020-10114-1 (opens in a new tab)PepBankPUB-33460002
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In adults with compensated HBV-induced cirrhosis, the cumulative incidence of liver-related events was similar for the three treatment groups, including entecavir plus thymosin-alpha1.

    In plain wordsIn adults with HBV cirrhosis, liver-related events were about equally common with entecavir, entecavir plus thymosin-alpha1, or lamivudine plus adefovir.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCumulative incidence of liver-related events by treatment group
    Study

    n = 937

    Comparator
    ETV; LAM + ADV
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    and was similar for three treatment groups.
    2 context sentences
    Summary · context
    Prospective cohorts of treatment-naïve adults with compensated HBV-induced cirrhosis were enrolled. Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).
    Summary · context
    Totally 937 patients were included, 608 patients treated with ETV, 252 with ETV + Thy-α1, and 77 with LAM + ADV.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01943617

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Beijing Friendship Hospitaln = 606Jun 2013 to Dec 2016

Liver Cirrhosis

Trial pageClinicalTrials.govUpdated 27 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.